Effect of Short-Time BelAgeTM Prescription on Pregnancy and Risk Preeclampsia

Introduction: The aim was to determine if one month taking BelAgeTM in the second trimester of pregnancy could reduce the risk of preeclampsia. Methods: From April 2019 to July 2020, a non-blinded, prospective, randomized, study was performed inviting women in the second trimester of pregnancy to take 3 g of BelAgeTM once daily for one month. The control group received only the nutritional assessment. Relative risk (RR) to develop preeclampsia with 95% confidence interval (CI) was calculated using the Social Science Statistics online software, considering a significant statistical value a P-value < 0.05. Results: 144 patients from the BelAgeTM group (mean age 23.6 ± 9.7), and 99 from the control group (mean age 22.1 ± 8.6) were included, finding differences basal systolic blood pressure (P = 0.03), final diastolic blood pressure (P = 0.002) and final mean blood pressure (P = 0.001). Preeclampsia was developed by 18 patients in the BelAgeTM group versus ten patients in the control group, RR 1.2 (95% CI, 0.60–2.57, P = 0.57). Conclusion: A short-time BelAgeTM prescription in the second trimester of pregnancy was enough to reduce the DBP, but did not reduce the risk of developing preeclampsia. Keywords: BelAgeTM diastolic blood pressure, preeclampsia, relative risk.